α-Adrenolytic Treatment of the Congenital Neuropathic Bladder

Stockamp, K.; Schreiter, F.

doi:10.1159/000279957

Cited by 28 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…If one observes a funnel-shaped widening of the trigonum ( = positive answer) within 10 minutes after the intravenous injection of 10 to 15 mg of phentolamine mesylate (alpha-blocking agent), one may assume that the alpha-receptors at the trigonal level are a direct contributing factor responsible for the chronic retention. Over the past 8 years we have observed that this category of patient generally responds well to long-term oral alpha-adrenolytic treatment with phenoxybenzamine hydro chloride (Krane & Olssen, 1973;Mobley, 1976;Stockamp & Schreiter, 1975).…”

Section: Neuropharmacology and Urodynamicsmentioning

confidence: 97%

Clinical and urodynamic assessment of alpha-adrenolytic therapy in patients with neurogenic bladder function

Hachen¹

1980

Spinal Cord

View full text Add to dashboard Cite

Abstract. The efficacy of alpha-adrenolytic treatment with oral phenoxybenzamine chloride (40 mg per day during three to four months) has been assessed both clinically and urodynamically among 249 patients with neurogenic bladder function. The results were significantly better in patients with autonomous (n = 95) than in the ones with automatic (n = 154) bladders (urethral sphincter spasticity and detrusor sphincter dyssynergia dominating the clinical picture in the latter event). A further striking difference was noticed when the data were analysed with regard to the patient's age, a far better therapeutic response being regularly recorded in subjects below age 35, while minimal and inconsistent improvements were observed in the older age group. No major side effects were encountered.Caution is however required in tetraplegics where phenoxybenzamine may aggravate orthostatic hypotension. On the other side the drug proves highly beneficial in these same patients in that it markedly lowers the incidence of dysreflexic states.

show abstract

Section: Neuropharmacology and Urodynamicsmentioning

confidence: 97%

Clinical and urodynamic assessment of alpha-adrenolytic therapy in patients with neurogenic bladder function

Hachen¹

1980

Spinal Cord

View full text Add to dashboard Cite

show abstract

“…Die Idee, den Blasenauslaßwiderstand bei neurogen bedingter Blasenentleerungsstörung mittels Gabe eines Alphablockers zu senken, ist keine neue (Amark and Nergardh, 1991;de 62 Voogt and van der Sluis, 1976;Seiferth, 1976;Stockamp and Schreiter, 1975) …”

Section: Therapie Einer Funktionellen Obstruktion Mittels Alphablockadeunclassified

Botulinumtoxin in der Urologie

Schulte-Baukloh

Knispel

2004

Urologe [A]

View full text Add to dashboard Cite

“…Alpha adrenergic blocking agents have been shown to be useful in the treatment of lower motor neuron bladder (Stockamp & Schreiter, 1975). In patients with lower motor neuron bladder and flaccid pelvic floor muscles the membranous urethra does not usually present an obstacle to voiding.…”

Section: Diagnosis and Treatment Past The Acute Post-traumatic Periodmentioning

confidence: 99%

From intermittent catheterisation to catheter freedom via urodynamics: a tribute to Sir Ludwig Guttmann

Rossier

Fam

1979

Spinal Cord

View full text Add to dashboard Cite

show abstract

α-Adrenolytic Treatment of the Congenital Neuropathic Bladder

Cited by 28 publications

References 0 publications

Clinical and urodynamic assessment of alpha-adrenolytic therapy in patients with neurogenic bladder function

Clinical and urodynamic assessment of alpha-adrenolytic therapy in patients with neurogenic bladder function

Botulinumtoxin in der Urologie

From intermittent catheterisation to catheter freedom via urodynamics: a tribute to Sir Ludwig Guttmann

Contact Info

Product

Resources

About